Literature DB >> 20500805

T2 lesions and rate of progression of disability in multiple sclerosis.

J P Mostert1, M W Koch, C Steen, D J Heersema, J C De Groot, J De Keyser.   

Abstract

BACKGROUND AND
PURPOSE: To assess the predictive value of T2 lesions on the rate of progression of disability in multiple sclerosis (MS).
METHODS: We reanalyzed T2 lesion number and load on brain MRI scans, performed before 1997, of 186 MS patients, who were clinically followed. There were 90 patients with progressive MS (35 secondary progressive and 55 primary progressive), and 96 with relapsing remitting MS. The rate of progression of disability was measured by time to sustained progression of disability (defined as an increase in ≥ 1 point when the Expanded Disability Status Scale (EDSS) was 5.5 or less and an increase in EDSS of ≥ 0.5 point when the EDSS was 6.0 or higher), and by the Multiple Sclerosis Severity Score (MSSS).
RESULTS: During follow-up (median 15 years, IQR 12-17 years), 94% of the patients with progressive MS and 50% of the patients with relapsing remitting MS had progression of disability. Higher T2 lesion number and load were modestly associated with a higher rate of disease progression on the MSSS and a shorter time to progression of disability in relapsing remitting MS, but not in progressive MS.
CONCLUSIONS: Our findings indicate that the amount of T2 lesions has a small predictive value for progression of disability in relapsing remitting MS, but has no influence on the rate of progression in progressive MS.
© 2010 The Author(s). European Journal of Neurology © 2010 EFNS.

Entities:  

Mesh:

Year:  2010        PMID: 20500805     DOI: 10.1111/j.1468-1331.2010.03093.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

Review 1.  The role of advanced magnetic resonance imaging techniques in primary progressive MS.

Authors:  Maria A Rocca; Martina Absinta; Massimo Filippi
Journal:  J Neurol       Date:  2011-08-04       Impact factor: 4.849

Review 2.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

3.  MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.

Authors:  Giancarlo Comi; Stuart D Cook; Gavin Giovannoni; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony C Hamlett; Vissia Viglietta; Steven J Greenberg
Journal:  J Neurol       Date:  2012-12-21       Impact factor: 4.849

4.  High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years.

Authors:  Nermin Serbecic; Fahmy Aboul-Enein; Sven C Beutelspacher; Clemens Vass; Wolfgang Kristoferitsch; Hans Lassmann; Andreas Reitner; Ursula Schmidt-Erfurth
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

5.  A comprehensive approach to the segmentation of multichannel three-dimensional MR brain images in multiple sclerosis.

Authors:  Sushmita Datta; Ponnada A Narayana
Journal:  Neuroimage Clin       Date:  2013-01-11       Impact factor: 4.881

6.  Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study.

Authors:  Laura E Jonkman; Alexandra Lopez Soriano; Sandra Amor; Frederik Barkhof; Paul van der Valk; Hugo Vrenken; Jeroen J G Geurts
Journal:  J Neurol       Date:  2015-03-13       Impact factor: 4.849

7.  Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Authors:  Peter Connick; Floriana De Angelis; Richard A Parker; Domenico Plantone; Anisha Doshi; Nevin John; Jonathan Stutters; David MacManus; Ferran Prados Carrasco; Frederik Barkhof; Sebastien Ourselin; Marie Braisher; Moira Ross; Gina Cranswick; Sue H Pavitt; Gavin Giovannoni; Claudia Angela Gandini Wheeler-Kingshott; Clive Hawkins; Basil Sharrack; Roger Bastow; Christopher J Weir; Nigel Stallard; Siddharthan Chandran; Jeremy Chataway
Journal:  BMJ Open       Date:  2018-08-30       Impact factor: 2.692

8.  Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI.

Authors:  Eloy Martínez-Heras; Elisabeth Solana; Ferran Prados; Magí Andorrà; Aleix Solanes; Elisabet López-Soley; Carmen Montejo; Irene Pulido-Valdeolivas; Salut Alba-Arbalat; Nuria Sola-Valls; Maria Sepúlveda; Yolanda Blanco; Albert Saiz; Joaquim Radua; Sara Llufriu
Journal:  Neuroimage Clin       Date:  2020-09-09       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.